Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Etrolizumab open-label extension and safety monitoring in Crohn's disease
NL-OMON47567Phase 3Recruiting
- Sponsor
- Roche
- Start
- Jul 2016
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, open-label trial of Etrolizumab in Crohn's disease and inflammatory bowel disease (IBD) (2 arms), sponsored by Roche. Started Jul 2016; status: recruiting.
02
Drugs
Etrolizumab
03
Conditions
Crohn's diseaseinflammatory bowel disease (IBD)
Beyond the preview
Go deeper on NL-OMON47567.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON47567.